Search dm+d | Analyse prescribing for this drug | See prices paid for this drug and its variants
Name | Aliskiren 300mg tablets |
BNF code | 0205053A0AAABAB |
Virtual Therapeutic Moiety | Aliskiren |
Date identifier became valid | 27 May 2021 |
Previous product identifier | 425669009 |
Basis of preferred name | rINN - Recommended International Non-proprietary |
Prescribing status | Valid as a prescribable product |
Sugar free | ✗ |
Gluten free | ✗ |
Preservative free | ✗ |
CFC free | ✗ |
Dose form | Discrete |
Unit dose form size | 1.000 |
Unit dose form units | tablet |
Unit dose unit of measure | tablet |
Virtual Product Ingredient | |
---|---|
Ingredient | Aliskiren hemifumarate |
Basis of pharmaceutical strength | Based on Base Substance |
Basis of strength substance identifier | 426725002 |
Strength value numerator | 300.000 |
Strength value numerator unit | mg |
Ontology Drug Form & Route | |
Form & Route | tablet.oral |
Dose Form | |
Formulation | Oral tablet |
Drug Route | |
Route | Oral |
Controlled Drug Prescribing Information | |
Controlled Drug category | No Controlled Drug Status |
Actual Medicinal Products | |
Rasilez 300mg tablets (CST Pharma Ltd) | |
Rasilez 300mg tablets (Lexon (UK) Ltd) | |
Rasilez 300mg tablets (Noden Pharma DAC) | |
Rasilez 300mg tablets (Sigma Pharmaceuticals Plc) | |
Virtual Medicinal Product Packs | |
Aliskiren 300mg tablets 28 tablet | |
Aliskiren 300mg tablets 30 tablet |
dm+d data retrieved from TRUD: release NHSBSA_11.0.0_20241104000001, imported on 5th November 2024 at 03:47:41.